Viridian Therapeutics Inc (VRDN NASDAQ) stock market data APIs
$25.244
-0.57(-2.3%)
as of November 2, 2026
Try our APIs with
free plan!
Viridian Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Prev. Close
25.244
Open
24.676
High
25.8165
Low
24.0028
52 wk Range
13.18-34.29
Market Cap
2 795 M
Shares Outstanding
113 M
Revenue
71 127 K
Beta
1.104
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Viridian Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viridian Therapeutics Inc data using free add-ons & libraries
Get Viridian Therapeutics Inc Fundamental Data
Viridian Therapeutics Inc Fundamental data includes:
- Net Revenue: 71 127 K
- EBITDA: -404 731 008
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Viridian Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-04
- EPS/Forecast: -1.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viridian Therapeutics Inc News
New
Viridian Metals Announces Private Placement of up to $5.0 Million of Flow-Through and Hard Dollar Units
OTTAWA, ON / ACCESS Newswire / October 29, 2026 / Viridian Metals Inc. (CSE:VRDN)(OTCQB:VIRMF) ("Viridian" or the "Company") is pleased to announce a non-brokered private placement (the "Private Place...
Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main
New assays support higher grades and substantially greater mineralized thicknesses than the initial Exploration Target OTTAWA, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VR...
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately gr...
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
The U.S. Food and Drug Administration on Friday approved Roche Holdings AG(OTC:RHHBY) Enspryng (satralizumab) for thyroid eye disease. The regulatory action provides patients with the sole at-home su...
Get Viridian Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.